The Health Information and Quality Authority (HIQA) has recently initiated a public consultation regarding the potential inclusion of shingles vaccination (herpes zoster) within the national immunization program for adults. This strategic move is in direct response to a pivotal recommendation from the National Immunisation Advisory Committee (NIAC) and follows a specific request from the Department of Health. This assessment aims to provide the Minister for Health with comprehensive, evidence-based advice that will play a crucial role in shaping the decision-making process concerning the future direction of Ireland’s immunization schedule.
Shingles (herpes zoster), a viral infection that manifests as a painful blistering rash, is caused by the varicella-zoster virus, the same virus responsible for chickenpox. This condition predominantly targets the older demographic, especially individuals aged over 50, but also poses a significant threat to those with weakened immune systems. Notably, the risk and severity of shingles (herpes zoster) increase with age, underscoring the importance of considering vaccination for these at-risk groups. Despite the clear need and the availability of shingles vaccines in Ireland, the Health Service Executive (HSE) currently does not subsidize these vaccines, which necessitates individuals to bear the full cost of vaccination out of pocket.
HIQA Consultation Seeks to Revolutionize Shingles Vaccination Policy in Ireland
The consultation launched by HIQA marks a critical step towards addressing this gap in the healthcare system, seeking to gather input from a broad spectrum of stakeholders, including medical professionals, patients, and the general public. This inclusive approach aims to ensure that the final recommendation to the Minister for Health is reflective of a wide range of perspectives and needs. Furthermore, the outcome of this consultation could lead to significant changes in how shingles vaccinations are administered and funded in Ireland, potentially making these vaccines more accessible to those who need them most. The proactive engagement of HIQA in this process demonstrates a commitment to enhancing public health policy through informed, evidence-based decision-making.
HIQA’s comprehensive assessment targets adults aged 50 and above, along with those aged 18 and over who are at an elevated risk of contracting shingles. Dr. Conor Teljeur, HIQA’s Chief Scientist, has remarked on the vaccine’s safety and efficacy. Despite its benefits, the vaccine’s effectiveness wanes over time, leading to discussions about its economic viability. According to Dr. Teljeur, incorporating the shingles vaccine into the routine immunization schedule for the general populace aged 50 and above might not represent an efficient allocation of HSE resources, given the current vaccine pricing.
HIQA’s Review of Shingles Vaccine Inclusion in Ireland’s Immunization Schedule
To foster transparency and engage with the public, HIQA has released its preliminary findings, inviting feedback from the community. An online survey, along with detailed instructions on participating in the consultation, is accessible on HIQA’s official website. The consultation window is slated to close at 5 pm on Tuesday, 30 April 2024. The ensuing feedback will be integrated into the final report, which will then be presented to the Minister for Health and published on the HIQA website.
The potential inclusion of the shingles vaccine in the adult immunization schedule poses a significant public health consideration. Shingles affects about one in three individuals who have previously contracted chickenpox, signifying a substantial portion of the population. Despite the licensure and marketing of herpes zoster vaccines in Ireland, their exclusion from the national immunization schedule prompts a reevaluation of public health strategies to protect vulnerable populations better.
Resource: HIQA, March 19, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
